The aim of this study was to provide an economic evaluation of lorlatinib for advanced ALK+ NSCLC patients who had previously received no systemic treatment for metastatic disease to better understand its value from the US healthcare payer perspective. The gene discussed is ALK; the disease is non-small cell lung carcinoma.